Using nebulized dexmedetomidine to manage heart response during bariatric surgery
Effect of Preoperative Nebulized Dexmedetomidine on Hemodynamic Changes in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery.
This study tests if using a mist of dexmedetomidine can help control heart responses during bariatric surgery for people who are severely obese.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta, ElGharbia) |
| Trial ID | NCT06014359 on ClinicalTrials.gov |
What this trial studies
This randomized study evaluates the effects of nebulized dexmedetomidine on hemodynamic responses during laparoscopic bariatric surgery in morbidly obese patients. The study focuses on how this α-2 adrenergic agonist can blunt the hemodynamic changes associated with laryngoscopy, intubation, and pneumoperitoneum. By utilizing a noninvasive nebulization method, the research aims to provide an alternative to traditional intravenous or intranasal drug administration, potentially improving patient outcomes and comfort during surgery.
Who should consider this trial
Good fit: Ideal candidates for this study are adult morbidly obese patients aged 18-50 with a BMI between 40-50, scheduled for elective laparoscopic bariatric surgery.
Not a fit: Patients with decompensated hepatic, renal, or cardiac disease, uncontrolled hypertension, or those with psychiatric disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to better management of hemodynamic responses during surgery, reducing complications and improving recovery times for patients.
How similar studies have performed: While the use of dexmedetomidine has been explored in various administration routes, this specific approach of nebulization in the context of laparoscopic bariatric surgery is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * This study will include 90 adult morbidly obese patients of both sex with BMI (40-50), (ASA) III physical status, aged between 18 -50 years scheduled for elective laparoscopic bariatric surgery under general anesthesia. Exclusion Criteria: 1. Patient's refusal. 2. Decompensated hepatic or renal or cardiac disease. 3. Expected difficult airway management. 4. Uncontrolled hypertension. 5. Psychiatric disease. 6. Sever pulmonary disorders. 7. Patients on opioid, alcohol, beta-blockers or allergy to any of the study drugs.
Where this trial is running
Tanta, ElGharbia
- Tanta University — Tanta, ElGharbia, Egypt (Recruiting)
Study contacts
- Principal investigator: Abdelhamed I Badreldin, MBBCH — Resident of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.
- Study coordinator: Abdelhamed I Badreldin, MBBCH
- Email: ai0751294@gmail.com
- Phone: 00201090690631
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.